Biocryst Pharmaceuticals (BCRX) Gross Margin (2010 - 2026)

Biocryst Pharmaceuticals' Gross Margin history runs 16 years deep, the most recent figure standing at 96.56% for Q1 2026.

• Quarterly Gross Margin fell 30.0% year-over-year to 96.56% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 95.86% (down 105.0% YoY) and the FY2025 annual result came in at 97.82%, up 54.0% from the prior year.
• Gross Margin was 96.56% for Q1 2026 at Biocryst Pharmaceuticals, up from 1244.92% in the prior quarter.
• Across five years, Gross Margin topped out at 99.62% in Q2 2022 and bottomed at 1244.92% in Q4 2025.
• A 5-year average of 18.9% and a median of 98.33% in 2023 frame the typical range for Gross Margin.
• Annual changes were most pronounced in 2022 — Gross Margin jumped 3060 bps — and 2025, when it sank 134028 bps.
• Biocryst Pharmaceuticals' Gross Margin stood at 97.0% in 2022, then increased by 1 bps to 98.33% in 2023, then slipped by 3 bps to 95.37% in 2024, then plunged by 1405 bps to 1244.92% in 2025, then jumped by 108 bps to 96.56% in 2026.
• Business Quant data shows BCRX's Gross Margin at 96.56% in Q1 2026, 1244.92% in Q4 2025, and 98.63% in Q3 2025.